Figure 3
From: CLDN15 is a novel diagnostic marker for malignant pleural mesothelioma
CLDN15 is expressed in MPM tissues. a Typical staining patterns of anti-CLDN15 (2C11) mAb exhibiting strong to weak staining intensities. Scale bar, 50 µm. b IHC of epithelioid-, biphasic- and sarcomatoid-type MPMs using anti-CLDN15 (2C11), anti-calretinin, anti-D2-40 and anti-WT1 antibodies. “E” and “S” in the HE staining panel of the biphasic-type MPM indicate the epitheliod-type and sarcomatoid-type cell regions, respectively. c IHC of lung adenocarcinomas using anti-CLDN15 (2C11) mAb. d Distribution of IRS scores in MPMs and lung adenocarcinomas. e–g IHC of lung squamous cell carcinomas (e), chest wall fibrosarcoma (f) and abdominal wall fibrosarcoma (g) using anti-CLDN15 (2C11) mAb.
